ClinVar Miner

Submissions for variant NM_001079866.2(BCS1L):c.205C>T (p.Arg69Cys)

gnomAD frequency: 0.00011  dbSNP: rs377025174
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000197059 SCV000251193 likely pathogenic not provided 2023-04-26 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 19508421, 17403714, 17314340, 12215968, 11528392, 31435670, 34662929, 27959697)
Ambry Genetics RCV000623904 SCV000740812 likely pathogenic Inborn genetic diseases 2015-03-11 criteria provided, single submitter clinical testing
Invitae RCV000197059 SCV001205466 pathogenic not provided 2024-01-09 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 69 of the BCS1L protein (p.Arg69Cys). This variant is present in population databases (rs377025174, gnomAD 0.03%). This missense change has been observed in individual(s) with clinical features of mitochondrial complex III deficiency (PMID: 27959697, 31435670; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 214160). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BCS1L protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BCS1L function (PMID: 31435670). For these reasons, this variant has been classified as Pathogenic.
Myriad Genetics, Inc. RCV001810436 SCV002060338 uncertain significance Pili torti-deafness syndrome; GRACILE syndrome; Mitochondrial complex III deficiency nuclear type 1 2021-11-01 criteria provided, single submitter clinical testing NM_004328.4(BCS1L):c.205C>T(R69C) is a missense variant classified as a variant of uncertain significance in the context of BCS1L-related disorders. R69C has been observed in cases with relevant disease (PMID: 31435670, 30634555, 27959697). Functional assessments of this variant are available in the literature (PMID: 31435670). R69C has been observed in population frequency databases (gnomAD: FIN 0.03%). In summary, there is insufficient evidence to classify NM_004328.4(BCS1L):c.205C>T(R69C) as pathogenic or benign. Please note: this variant was assessed in the context of healthy population screening.
Mendelics RCV000415034 SCV002518569 pathogenic Mitochondrial complex III deficiency nuclear type 1 2022-05-04 criteria provided, single submitter clinical testing
Baylor Genetics RCV000675122 SCV002583278 likely pathogenic GRACILE syndrome criteria provided, single submitter clinical testing
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV000415034 SCV002768359 pathogenic Mitochondrial complex III deficiency nuclear type 1 2022-02-02 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Bjornstad syndrome (MIM#262000), GRACILE syndrome (MIM#603358) and mitochondrial complex III deficiency, nuclear type (MIM#1124000). Missense variants have been reported to cause all conditions, with clinical severity dependant on the quantity and location of production of reactive oxygen species (PMID: 17314340). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to cysteine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (18 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (12 heterozygotes, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated import auxiliary sequence (PMID: 31435670). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as a VUS, but more commonly and recently as likely pathogenic. It has been reported in several compound heterozygous individuals with Leigh syndrome or aminoaciduria, seizures, bilateral sensorineural deafness and learning difficulties (ClinVar, LOVD, PMID: 31435670, PMID: 30634555). An additional individual with mitochondrial complex III deficiency has also been reported, but this individual had an additional hemizygous variant in the NLGN4X gene, which is considered part of a dual molecular diagnosis (PMID: 27959697, ClinVar). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1001 - This variant has strong functional evidence supporting abnormal protein function. Functional analysis of this variant using the muscle biopsy of an affected individual and yeast complementation assays, has demonstrated that this variant has a partial loss of function effect on protein activity.Additionally, it reduced protein expression, mitochondrial respiratory activity and complex III activity (PMID: 31435670). (SP) 1102 - Strong phenotype match for this individual. (SP) 1205 - This variant has been shown to be maternally inherited. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000675122 SCV003922924 pathogenic GRACILE syndrome 2023-03-27 criteria provided, single submitter clinical testing Variant summary: BCS1L c.205C>T (p.Arg69Cys) results in a non-conservative amino acid change located in the N-terminal domain (IPR014851) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.8e-05 in 251480 control chromosomes (gnomAD). This frequency is not higher than the estimated maximal expected for a pathogenic variant in BCS1L causing GRACILE Syndrome (0.00047), allowing no conclusion about variant significance. c.205C>T has been reported in the literature in multiple compound heterozygous individuals affected with symptoms that belong to the spectrum of BCS1L-related disorders (Olahova_2019, Hikmat_2021, Jou_2019, Posey_2017), all carrying a (likely) pathogenic variant in trans. These data indicate that the variant is likely to be associated with disease. At least one of these publications also reported experimental evidence, and demonstrated a partial loss of function in patient derived cells and in yeast complementation assays (Olahova_2019). Eight submitters have provided clinical-significance assessments for this variant in ClinVar after 2014, and classified the variant as pathogenic (n=3) / likely pathogenic (n=3) or VUS (n=2). Based on the evidence outlined above, the variant was classified as pathogenic.
Baylor Genetics RCV003474948 SCV004210796 likely pathogenic Pili torti-deafness syndrome 2023-08-31 criteria provided, single submitter clinical testing
Baylor Genetics RCV000415034 SCV000328852 uncertain significance Mitochondrial complex III deficiency nuclear type 1 2016-05-01 no assertion criteria provided clinical testing Our laboratory reported dual molecular diagnoses in BCS1L (NM_004328.4:c.598C>T; NM_004328.4:c.205C>T ; in trans) and NLGN4X (NM_181332.1:c.301C>T) in an individual with short stature, failure to thrive, rickets, Fanconi syndrome, delayed motor milestones, absent speech, developmental regression, intellectual disability, hypotonia, seizure disorder, gait ataxia, abnormal movements (laughing behavior and tongue protrusion), dysmorphic features, microcephaly, history of seizure disorder.
Natera, Inc. RCV000675122 SCV001455774 likely pathogenic GRACILE syndrome 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.